Telomerase Reverse Transcriptase

Advertisement

cGxPJobs Banner

Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1

CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...

By cGxPwire Editor
September 12, 2026

Read More

Advertisement

cGxPJobs

Directory